Design Therapeutics (DSGN) Current Assets (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Current Assets data on file, last reported at $227.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 2.82% year-over-year to $227.0 million; the trailing twelve-month figure through Mar 2026 stood at $227.0 million (down 2.82% YoY), and the FY2025 full-year result was $223.8 million, down 9.78% from the prior year.
• Current Assets rose to $227.0 million in Q1 2026, from $223.8 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $373.9 million in Q1 2022 to a low of $209.0 million in Q3 2025.
• A 5-year average of $281.2 million and a median of $273.9 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets decreased 18.74% in 2025 and fell 2.82% in 2026, its largest moves.
• Tracing DSGN's Current Assets over 5 years: stood at $335.1 million in 2022, then slipped by 15.08% to $284.6 million in 2023, then dropped by 12.84% to $248.0 million in 2024, then retreated by 9.78% to $223.8 million in 2025, then increased by 1.46% to $227.0 million in 2026.
• Business Quant data shows DSGN's Current Assets at $227.0 million in Q1 2026, $223.8 million in Q4 2025, and $209.0 million in Q3 2025.